INTEGRA supports ground-breaking brain tumour research
22 Dec 2021
INTEGRA Biosciences is proud to be supporting vital translational research into diffuse intrinsic ponsglioma (DIPG) – a rare childhood brain tumour – at the Ludwig Maximilian University of Munich (LMU) with a festive donation of 20,000 EUR.
Brain tumours in children are thankfully rare but are often associated with poor prognoses and low survival rates. Dr Alexander Beck’s DIPG Fighter research group focuses on finding new therapies for the disease, which usually affects children between five and nine years of age, with no significant long-term survival beyond five years. The group routinely uses a range of INTEGRA products – including the ASSIST PLUS pipetting robot, VOYAGER adjustable tip spacing pipettes, EVOLVE manual pipettes and PIPETBOY acu 2 pipette controllers. The company was delighted to be supporting the group’s valuable work with the donation.
Dr Beck said: “We are delighted to have been chosen as the recipient of this generous donation. We are dedicated to the rapid translation of drugs for paediatric brain tumours, with a particular emphasis on preclinical drug screening and testing. This donation will fund the continuation of our existing cutting-edge research projects, with the ultimate goal of identifying approved therapeutics that can be repurposed for new clinical applications.”
Dr Lukas Keller, Marketing Communications Director at INTEGRA, added: “We love encouraging initiatives that make the world a better place and this year we’ve been able to pledge 20,000 Euros to help advance the ground-breaking brain tumour research conducted at the LMU. We are excited to see how this festive contribution will be used to help children around the world with this disease.”